Comparing outcomes using low‐dose apixaban and anti‐Xa monitoring and vitamin K antagonists in patients with renal replacement therapy
Open Access
- 4 September 2026
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
Abstract
Background: Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT). Aim: To compare thrombotic and safety outcomes in patients receiving either vitamin K antagonists (VKAs) or apixaban 2.5 mg twice daily in the context of ESRD and RRT. Method: Retrospective service evaluation comparing bleeding and thrombotic outcomes in patients treated with apixaban 2.5 mg BD or VKA in a tertiary anticoagulation clinic. Trough anti‐Xa levels of apixaban patients were reviewed. Clinical features and outcomes were reviewed using electronic patient records. Results: Fifty‐five VKA and 33 apixaban patients were included in the analysis. There were no major bleeds in the apixaban cohort compared with 4 (7.3%) in the VKA cohort ( χ 2 = 2.667, p = 0.102). No difference in time to major or clinically relevant non‐major bleeding (CRNMB) was found ( χ 2 = 1.252, p = 0.263). Rates of thrombotic events (all stroke) were 1 vs . 3 (1.1 and 7.1 events/100 patient‐years) for VKA and apixaban, respectively ( χ 2 = 3.291, p = 0.070). Only one stroke was related to AF. Eighty‐four of 85 trough anti‐Xa levels analysed were below the upper limit of normal of the reference range for the general population. Discussion: Our results suggest similar outcomes with VKA and apixaban in those receiving RRT, indicating apixaban may be a viable second‐line treatment option in those for whom VKA may not be appropriate. Further investigation into the safety of the apixaban 5‐mg regimen is warranted.Keywords
This publication has 22 references indexed in Scilit:
- 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal, 2024
- Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration PatientsKidney International Reports, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysisJournal of the American Pharmacists Association, 2023
- Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE)Thrombosis Research, 2022
- Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial FibrillationSeminars in Nephrology, 2018
- Safety and effectiveness of apixaban compared to warfarin in dialysis patientsResearch and Practice in Thrombosis and Haemostasis, 2018
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011